NCT02038790已完成4 期
A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Overall Intervention Preference As Assessed by Participants
研究概览
简要总结
The primary objective of this study is to compare overall patient preference for either Suboxone® sublingual film 8/2 or Zubsolv® sublingual tablets 5.7/1.4. Suboxone sublingual film 8/2 contains 8mg buprenorphine and 2mg naloxone. Zubsolv sublingual tablets contain 5.7 mg buprenorphine and 1.4 mg naloxone. Both interventions act as a substitute for opiate drugs like heroin, morphine or oxycodone and help withdrawal from opiate drugs over a period of time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •currently on a single daily dose of 8/2 of Suboxone or generic equivalent, or 5.7/1.4 mg Zubsolv for treatment of opioid dependence that has been medically confirmed.
- •in good general health with no specific contraindication for treatment with buprenorphine or naloxone.
- •the ability to understand, sign and date written consent and Health Information Portability and Accountability Act (HIPAA) authorization forms, which must be obtained prior to any study related procedures being completed.
- •Female subjects must be postmenopausal for at least 2 years, surgically sterile (i.e. tubal ligation, hysterectomy, or bilateral ovariectomy), or practicing an effective method of contraception during the study with one of the following methods: oral contraception, intrauterine device (IUD), abstinence, contraceptive injections, conscientious use of a diaphragm or condoms and spermicidal foam, systemic (implant) contraception or partner has had a vasectomy.
排除标准
- •Subject is taking other opioids (other than buprenorphine/naloxone) that may interfere with the study evaluations or compromise the safety of the subject.
- •Subject is not able to read or have other impairments that may prevent completion of questionnaires or other study evaluations
- •Subject has open sores present in the oral cavity.
- •Subject has participated in any previous clinical testing involving investigational drug within the 4 weeks prior to study start.
- •Subject is pregnant, lactating or planning a pregnancy
- •Subject is currently participating in any other type of clinical testing.
- •Subject has a medical condition that in the Investigator's opinion could affect the taste assessments required by the study
- •Subject is judged by the Investigator after reviewing medical history to be unsuitable for any other reason that may either place the subject at increased risk during participation or interfere with the interpretation of the study outcomes.
研究组 & 干预措施
Suboxone sublingual film 8/2
Experimental
Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
干预措施: Suboxone Sublingual Film (Drug)
Zubsolv sublingual tablets 5.7/1.4
Active Comparator
Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
干预措施: Zubsolv sublingual tablets (Drug)
结局指标
主要结局
Overall Intervention Preference As Assessed by Participants
时间窗: Day 1
At the conclusion of Study Day 1, participants completed a study exit product comparison questionnaire. This outcome summarizes the percentage of participant answers to the question: When thinking about the two medications you evaluated over the last two days, which medication type did you prefer?
次要结局
- Percentage of Participant Response to the Question: Did You Experience Any Uncomfortable Effects of Burning or Stinging?(Days 0-1)
- Participant Preference With Regard to Overall Taste of Interventions(Day 1)
- Participant Assessments With Regard to Ease of Dissolution of Interventions(Day 1)
- Percentage of Participant Response to the Question: Compared to the Medication That You Are Currently Using for Treatment of Opioid Dependence, The Study Medication You Just Used Was.....(Days 0-1)
- Percentage of Participant Favorable and Unfavorable Response to the Question: How Easy or Difficult Was it to Open the Package?(Days 0-1)
- Percentage of Participant Favorable and Unfavorable Response to the Question: How Easy or Difficult Were the Package Instructions to Follow?(Days 0-1)
- Dissolution Time of Intervention as Recorded by a Trained Observer(Days 0-1)
- Percentage of Participant Favorable and Unfavorable Response to the Question: How Comfortable Did It Feel In Your Mouth?(Days 0-1)
- Percentage of Participant Favorable and Unfavorable Response to the Question: How Easily Did the Medication Dissolve in Your Mouth?(Days 0-1)
- Percentage of Participant Response to the Question: Did You Experience Any Uncomfortable Effects of Skin Irritation or Blisters?(Days 0-1)
- Percentage of Participant Response to the Request: Please Rate the Medication You Received Today in Terms of the Drug's Ability to Product a 'High'(Days 0-1)
- Percentage of Participant Response to the Request: When Thinking About the Medication You Used Today, Indicate on the Line Below Your Ability to Abuse This Medication(Days 0-1)
- Percentage of Participant Response to the Question: If You Did Want to Abuse This Medication, Would You Prefer to......(Days 0-1)
- Change From Baseline in Subject Opiate Withdrawal Scale (SOWS)(Day 0 prior to dosing, end of Day 0 (post dose), end of Day 1 (post dose))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1Opioid-Related DisordersNCT00078117University of California, Los Angeles516
已完成
4 期
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With InsomniaInsomniaHypertensionNCT02849184Jichi Medical University82
撤回
4 期
Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent AdolescentsOpiate AddictionNCT01015066State University of New York at Buffalo
撤回
4 期
Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery PopulationAddiction OpiateChronic PainFractures, BoneBuprenorphine DependenceNCT04464512West Virginia University
已完成
1 期
Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on ApplesauceHealthyNCT00759954Actavis Inc.36